Published in J Clin Virol on April 01, 2001
A Pilot Study of the Safety, Tolerability, and Effectiveness of Halo | NCT02644135
Human rhinoviruses. Clin Microbiol Rev (2013) 2.05
The ABCs of rhinoviruses, wheezing, and asthma. J Virol (2010) 1.89
Assay for 5' noncoding region analysis of all human rhinovirus prototype strains. J Clin Microbiol (2008) 1.59
Amplicon sequencing and improved detection of human rhinovirus in respiratory samples. J Clin Microbiol (2004) 1.49
Diagnostic value of real-time polymerase chain reaction to detect viruses in young children admitted to the paediatric intensive care unit with lower respiratory tract infection. Crit Care (2006) 1.32
Human bocavirus in children with acute lymphoblastic leukemia. Eur J Pediatr (2007) 1.17
Rate and influence of respiratory virus co-infection on pandemic (H1N1) influenza disease. J Infect (2011) 1.14
Respiratory viruses other than influenza virus: impact and therapeutic advances. Clin Microbiol Rev (2008) 1.05
Rhinoviruses, allergic inflammation, and asthma. Immunol Rev (2011) 0.99
Clinical severity of rhinovirus/enterovirus compared to other respiratory viruses in children. Influenza Other Respir Viruses (2014) 0.92
Epidemiology and clinical outcome of virus-positive respiratory samples in ventilated patients: a prospective cohort study. Crit Care (2006) 0.89
Specific viruses detected in nigerian children in association with acute respiratory disease. J Trop Med (2011) 0.89
Viral respiratory infection and the link to asthma. Pediatr Infect Dis J (2008) 0.84
Human rhinovirus infections of the lower respiratory tract in hematopoietic stem cell transplant recipients. Transpl Infect Dis (2013) 0.77
The impact of human rhinovirus infection in pediatric patients undergoing heart surgery. Pediatr Cardiol (2014) 0.75
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med (1998) 6.75
Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J (2001) 4.93
Influenza virus neuraminidase inhibitors. Lancet (2000) 4.89
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res (2002) 4.85
Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis (2001) 3.69
Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother (1980) 3.60
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr (2000) 3.53
Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet (1999) 3.43
Critical care nurse practitioners: evolution of the advanced practice nursing role. Am J Crit Care (1994) 3.22
Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol (2003) 2.92
Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res (2001) 2.91
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis (2000) 2.90
Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses. Am J Respir Crit Care Med (1999) 2.76
Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol (2001) 2.58
Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob Agents Chemother (1983) 2.53
Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA (1981) 2.50
Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother (2001) 2.46
Risk factors for acute wheezing in infants and children: viruses, passive smoke, and IgE antibodies to inhalant allergens. Pediatrics (1993) 2.41
Frequency and natural history of rhinovirus infections in adults during autumn. J Clin Microbiol (1997) 2.09
Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis (1999) 2.03
Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob Agents Chemother (1981) 1.99
Performance of virus isolation and Directigen Flu A to detect influenza A virus in experimental human infection. J Clin Virol (1999) 1.98
Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction. Pediatrics (1998) 1.94
Etiology of acute conjunctivitis in children. J Pediatr (1981) 1.92
Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis (1998) 1.85
Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis (1995) 1.84
Picornavirus infections: a primer for the practitioner. Arch Fam Med (2000) 1.80
Detection of rhinovirus in sinus brushings of patients with acute community-acquired sinusitis by reverse transcription-PCR. J Clin Microbiol (1997) 1.76
Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect Dis Clin North Am (1987) 1.73
The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology (1997) 1.70
Comparison of the Immulok cultureset kit and virus isolation for detection of herpes simplex virus in clinical specimens. J Clin Microbiol (1983) 1.64
Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother (1992) 1.59
Rapid diagnosis of influenza A and B by 24-h fluorescent focus assays. J Clin Microbiol (1988) 1.57
Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med (1986) 1.56
Clinical relevance of cytomegalovirus viraemia(*,†). HIV Med (2011) 1.55
Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother (1999) 1.49
Epidemiologic evidence for Lancefield group C beta-hemolytic streptococci as a cause of exudative pharyngitis in college students. J Clin Microbiol (1997) 1.45
Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS (1999) 1.44
In vitro activity of zinc salts against human rhinoviruses. Antimicrob Agents Chemother (1987) 1.40
Prevalence of heartworm infection in healthy cats in the lower peninsula of Michigan. J Am Vet Med Assoc (2000) 1.40
Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Infect Dis (2000) 1.40
Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. Clin Infect Dis (2016) 1.39
Detection of human rhinovirus RNA in nasal washings by PCR. Mol Cell Probes (1993) 1.39
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (1999) 1.36
Chemotherapy of rhinovirus colds. Antimicrob Agents Chemother (1988) 1.30
Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness. J Infect Dis (1983) 1.30
Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. N Engl J Med (1997) 1.29
Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrob Agents Chemother (1985) 1.29
Human infection by a swine influenza A (H1N1) virus in Switzerland. Arch Virol (2003) 1.29
Enteric infections and diarrhea in human immunodeficiency virus-infected persons: prospective community-based cohort study. Swiss HIV Cohort Study. Arch Intern Med (1999) 1.28
Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA (1999) 1.28
Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob Agents Chemother (1980) 1.28
Parametric and genetic analysis of Drosophila appetitive long-term memory and sugar motivation. Genes Brain Behav (2009) 1.27
Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J Infect Dis (1991) 1.27
Activity of 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile (MDL-860) against picornaviruses in vitro. Antimicrob Agents Chemother (1982) 1.27
Enterovirus meningitis in adults. Clin Infect Dis (1998) 1.25
Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrob Agents Chemother (1982) 1.22
Localization of human rhinovirus replication in the upper respiratory tract by in situ hybridization. J Infect Dis (1995) 1.21
Respiratory viruses in bronchoalveolar lavage: a hospital-based cohort study in adults. Thorax (2009) 1.20
Comparative susceptibilities of human embryonic fibroblasts and HeLa cells for isolation of human rhinoviruses. J Clin Microbiol (1996) 1.19
Alterations of the eustachian tube, middle ear, and nose in rhinovirus infection. Arch Otolaryngol Head Neck Surg (1989) 1.18
In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antiviral Res (2000) 1.18
Adenovirus type 8 epidemic keratoconjunctivitis in an eye clinic: risk factors and control. J Infect Dis (1993) 1.17
Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res (1997) 1.15
Response of HIV RNA to didanosine as a predictive marker of survival. AIDS (1995) 1.15
Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob Agents Chemother (1986) 1.13
Relapse of herpes simplex encephalitis after conventional acyclovir therapy. JAMA (1988) 1.13
The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer Dis Assoc Disord (2001) 1.13
New approaches to influenza chemotherapy. Neuraminidase inhibitors. Drugs (1998) 1.13
Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection. Antivir Ther (1999) 1.12
Acute respiratory viral infections in ambulatory children of urban northeast Brazil. J Infect Dis (1991) 1.12
Ineffectiveness of oral terfenadine in natural colds: evidence against histamine as a mediator of common cold symptoms. Pediatr Infect Dis J (1988) 1.11
Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds. Antimicrob Agents Chemother (1984) 1.11
Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS (2000) 1.10
Anti-interferon antibody increases rhinovirus isolation rates from nasal wash specimens containing interferon-alpha 2. Antiviral Res (1983) 1.10
Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am J Transplant (2008) 1.10
Rhinoviruses: important respiratory pathogens. Ann Med (1998) 1.09
Therapeutic effects of aerosolized amantadine in naturally acquired infection due to influenza A virus. J Infect Dis (1980) 1.08
In vitro studies of the antirhinovirus activity of soluble intercellular adhesion molecule-1. Antimicrob Agents Chemother (1992) 1.07
Rapid antigen testing for the surveillance of influenza epidemics. Clin Microbiol Infect (2003) 1.06
Acute febrile cerebrovasculitis: a syndrome of unknown, perhaps rickettsial, cause. Ann Intern Med (1986) 1.05
Increased interleukin-6 levels in nasal lavage samples following experimental influenza A virus infection. Clin Diagn Lab Immunol (1998) 1.04
Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds. J Infect Dis (1984) 1.04
Physiologic abnormalities in the paranasal sinuses during experimental rhinovirus colds. J Allergy Clin Immunol (1992) 1.04
Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med (2000) 1.03
Human tolerance and histopathologic effects of long-term administration of intranasal interferon-alpha 2. J Infect Dis (1983) 1.03
Effects of plant protease inhibitors, oryzacystatin I and soybean Bowman-Birk inhibitor, on the aphid Macrosiphum euphorbiae (Homoptera, Aphididae) and its parasitoid Aphelinus abdominalis (Hymenoptera, Aphelinidae). J Insect Physiol (2005) 1.02
Immunoblot studies to analyze antibody to the Rickettsia typhi group antigen in sera from patients with acute febrile cerebrovasculitis. J Clin Microbiol (1991) 1.00
Prophylactic efficacy and tolerance of low-dose intranasal interferon-alpha 2 in natural respiratory viral infections. Antiviral Res (1985) 0.99
Endothelial cells. Not just a cellophane wrapper. Arch Intern Med (1987) 0.98
Influenza transmission to recipient through lung transplantation. Transpl Infect Dis (2007) 0.98
Effect of rimantadine treatment on clinical manifestations and otologic complications in adults experimentally infected with influenza A (H1N1) virus. J Infect Dis (1998) 0.98
Endothelium-dependent flow-induced dilation of canine femoral and saphenous arteries. Blood Vessels (1986) 0.98